EUVIMEDEUVIMED entdecken
Crossref

Equivalent survival in targeted axillary dissection compared to axillary lymph node dissection in patients with node positive breast cancer receiving neoadjuvant chemotherapy

Callie Hlavin iD, Zainab Balogun, Danielle R Lavage, Michael S Cowher, Kristin Lupinacci, Quratulain Sabih, Atilla Soran, Jennifer G Steiman, Priscilla F McAuliffe, Emilia J Diego

Breast Cancer Research and Treatment · 2026

DOI: 10.1007/s10549-026-08078-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2026. Verfasst von Callie Hlavin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. hlavinca@upmc.edu. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Breast Neoplasms, Lymph Node Excision. Die Arbeit nennt 40 Literaturangaben. Gefördert von: NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The role of sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC) in node-positive breast cancer (N + BC) is evolving with opportunities to de-escalate surgery in those with complete axillary pathologic response. SLNB may lead to equivalent outcomes while avoiding the morbidity of axillary lymph node dissection (ALND). METHODS: This is a retrospective analysis of patients with N + BC who received NAC and targeted axillary dissection (TAD) with or without ALND from 2014 to 2021. Patients were categorized according to pathology of the previously positive radioactive seed marked lymph node into complete pathologic response (dSLN-) and persistent disease (dSLN+). We assessed the impact of axillary surgery on recurrence, disease-free survival (DFS), and overall survival (OS). RESULTS: We included 284 female patients with median follow-up of 36.3 months. 128 patients had dSLN-of which 13 (10.2%) had ALND and 115 (89.9%) had TAD. There were 156 dSLN+ patients: 107 (68.6%) ALND and 49 TAD. In both groups, TAD resulted in similar mortality (dSLN-: 15.4% vs. 8.9%, p=.309; dSLN+: 9.3% vs. 10.2%, p = 1.000), DFS (dSLN-:19.6 mos vs. 30.7 mos, p=.166; dSLN+: 30 mos vs. 37 mos, p=.650) and OS (dSLN-: 49.3 mos vs. 45.8 mos, p=.868; dSLN+: 36.4 months vs. 36.2 months, p=.982) compared to ALND. CONCLUSION: For patients with dSLN-, there was no difference in recurrence, mortality, DFS, or OS between ALND and TAD. While there was a higher frequency of recurrence in patients who had dSLN + and underwent ALND compared to TAD, there was no difference in DFS or OS. CLINICAL TRIALS NUMBER: Not applicable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyBreast NeoplasmsLymph Node ExcisionHumansFemaleAxillaRetrospective StudiesMiddle AgedAdultSentinel Lymph Node BiopsyLymphatic MetastasisAgedPathologic Complete ResponseLymph NodesDisease-Free SurvivalNeoplasm Recurrence, Local

Stichwörter der Autor:innen

Axillary de-escalationBreast cancerNeoadjuvant therapyTargeted axillary dissection

Autor:innen und Institutionen

  • Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. hlavinca@upmc.edu.
  • Department of Anesthesiology and Perioperative Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. hlavinca@upmc.edu.
  • Dept of Surgical Oncology, Hillman Cancer Center, University of Pittsburgh, Suite 414 5150 Centre Ave, Pittsburgh, PA, 15232, USA. hlavinca@upmc.edu.
  • University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Department of Anesthesiology and Perioperative Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Division of Surgical Oncology, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

ORCID-Profile: Callie Hlavin

Förderung

  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Hlavin, C., Balogun, Z., Lavage, D. R., Cowher, M. S., Lupinacci, K., Sabih, Q., Soran, A., Steiman, J. G., McAuliffe, P. F., & Diego, E. J. (2026). Equivalent survival in targeted axillary dissection compared to axillary lymph node dissection in patients with node positive breast cancer receiving neoadjuvant chemotherapy. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-026-08078-1

Vancouver

Hlavin C, Balogun Z, Lavage DR, Cowher MS, Lupinacci K, Sabih Q, et al. Equivalent survival in targeted axillary dissection compared to axillary lymph node dissection in patients with node positive breast cancer receiving neoadjuvant chemotherapy. Breast Cancer Research and Treatment. 2026. doi:10.1007/s10549-026-08078-1

BibTeX
@article{Hlavin2026,
  author = {Hlavin, Callie and Balogun, Zainab and Lavage, Danielle R and Cowher, Michael S and Lupinacci, Kristin and Sabih, Quratulain and Soran, Atilla and Steiman, Jennifer G and McAuliffe, Priscilla F and Diego, Emilia J},
  title = {Equivalent survival in targeted axillary dissection compared to axillary lymph node dissection in patients with node positive breast cancer receiving neoadjuvant chemotherapy},
  journal = {Breast Cancer Research and Treatment},
  year = {2026},
  doi = {10.1007/s10549-026-08078-1}
}
Kostenlos starten →